We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #3 (Hold) but that could change following its strong fourth quarter 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate for the current quarter is $1.39 per share, over the last 30 days. Quest Diagnostics’ fourth quarter adjusted earnings of $1.40 per share (up 6.9% year-over-year) has surpassed this estimate by a penny%.
Quest Diagnostics Incorporated Price and EPS Surprise
Revenues: Quest Diagnostics posted revenues of $1.94 billion in the reported quarter, up 4.1% year-over-year and beating the Zacks Consensus Estimate for revenues of $1.93 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 2.4% versus the prior year’s volume. However, revenue per requisition also increased 2.1% on a year-over-year basis.
Major Factors: Per management, the company made great progress in accelerating growth and driving operational excellence in 2017. The company announced seven acquisitions and exited the year exceeding the $1.3 billion goal of cumulative run rate Invigorate savings. Management has also stated that the company is a beneficiary of recent tax legislation, enabling the company to further improve earnings per share. The company has issued full-year 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Quest Diagnostics (DGX) Tops Q4 Earnings, Revenues Estimates
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #3 (Hold) but that could change following its strong fourth quarter 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate for the current quarter is $1.39 per share, over the last 30 days. Quest Diagnostics’ fourth quarter adjusted earnings of $1.40 per share (up 6.9% year-over-year) has surpassed this estimate by a penny%.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote
Revenues: Quest Diagnostics posted revenues of $1.94 billion in the reported quarter, up 4.1% year-over-year and beating the Zacks Consensus Estimate for revenues of $1.93 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 2.4% versus the prior year’s volume. However, revenue per requisition also increased 2.1% on a year-over-year basis.
Major Factors: Per management, the company made great progress in accelerating growth and driving operational excellence in 2017. The company announced seven acquisitions and exited the year exceeding the $1.3 billion goal of cumulative run rate Invigorate savings. Management has also stated that the company is a beneficiary of recent tax legislation, enabling the company to further improve earnings per share. The company has issued full-year 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>